Assessment of in vitro antigenotoxic effect of nigella sativa oil

Nigella sativa yağının in vitro antijenotoksik etkisinin değerlendirilmesi

Murat Zor¹, Elçin Latife Aslan²

¹Department of Pharmacognosy, Lokman Hekim University, Ankara, Turkey

²Department of Medical Biology, Lokman Hekim University, Ankara, Turkey

ABSTRACT

INTRODUCTION: Cyclophosphamide is an alkylating agent widely used as an antineoplastic and immunosuppressive agent. The genotoxicity of cyclophosphamide has been studied in a variety of in vivo and in vitro systems and is routinely used as a positive control in genotoxicity tests. Traditional medicine Nigella sativa L., (Nigella), Ranunculaceae family, especially in the Eastern Mediterranean countries, especially in many countries, and is widely used in many countries as a spice and folk medicine since the time of Dioscorides used as a plant. In this study, it was aimed to show the protective effects of Nigella sativa oil at different concentrations against the genotoxic effects of Cyclophosphamide by micronucleus test.

METHODS: For this purpose, healthy cells were treated in vitro with Nigella sativa oil at concentrations of 1, 5, 10 µg / mL and Cyclophosphamide as positive control for 68 hours. The micronuclei were then counted.

RESULTS: No significant increase in micronucleus frequency was observed when the application of Nigella Sativa oil at concentrations of 1, 5, 10 µg / mL compared with the negative control. There was a decrease in the number of micronucleus in all three concentrations (1, 5, 10 µg / mL) compared to the Cyclophosphamide group in the groups treated with Nigella sativa oil and cyclophosphamide.

DISCUSSION AND CONCLUSION: It has been shown that nigella sativa oil may have protective effects against genotoxicity agents in vitro. But more work is needed to understand the mechanism of the genotoxicity effects of nigella sativa oil.

Keywords: Cyclophosphamide, Nigella sativa oil, micronucleus, genotoxicity

ÖZ

GİRİŞ ve AMAÇ: Siklofosfamid, antineoplastik ve immünosüpresif ajan olarak yaygın olarak kullanılan alkilliyici bir ajandır. Siklofosfamid'in genotoksitesi çeşitli in vivo ve in vitro sistemde çalışılmış ve rutin olarak genotoksite testlerinde pozitif kontrol olarak kullanılmaktadır. Geleneksel tıp da Nigella sativa L., Ranunculaceae familyasından olup günümüzde başta Doğu Akdeniz ülkeleri olmak üzere birçok ülkede yaygın olarak yetişen ve hem baharat hem de halk ilacı olarak Dioscorides zamanından beri kullanılan bir bitkidir. Bu çalışmada Siklofosfamid'in genotoksik etkilerine karşı çörek otu yağının değişik konsantrasyonlardaki koruyucu etkilerinin mikronükleus testi ile gösterilmesi amaçlanmıştır.

YÖNTEM ve GEREÇLER: Bu amaçla, sağlıklı hücreler 1, 5, 10 µg/mL konsantrasyonlarında Nigella sativa yağı ile ve pozitif kontrol olarak Siklofosfamid ile 68 saat boyunca in vitro muamele edildi. Daha sonra ise mikronükleuslar sayıldı.

BULGULAR: *Nigella sativa* yağının 1, 5, 10 µg/mL konsantrasyonlarındaki uygulaması negatif kontrolle karşılaştırıldığında mikronükleus frekansında anlamlı bir artış gözlenmedi. *Nigella sativa* yağı ve Siklofosfamid'in birlikte uygulandığı gruplarda her üç konsantrasyonda da (1, 5, 10 µg/mL) Siklofosfamid grubuna göre mikronükleus sayısında azalma olduğu görüldü.

TARTIŞMA ve SONUÇ: *Nigella sativa* yağının genotoksisite ajanlarına karşı *in vitro* koruyucu etkilerinin olabileceği gösterilmiştir. *Nigella sativa* yağının genotoksisiteyi giderici etkilerinin mekanizmasının anlaşılması için daha fazla çalışmaya ihtiyaç vardır.

Anahtar Kelimeler: Siklofosfamid, *Nigella sativa* yağı, mikronükleus, genotoksisite

Murat Zor, Department of Pharmacognosy, Lokman Hekim University, Ankara, Turkey
murat.zor@lokmanhekim.edu.tr

0000-0001-6014-2930

0536 4956596

18.12.2019

02.01.2020

Introduction

Cyclophosphamide is an oxazophosphorine derivative of nitrogen mustard and is an alkylating agent commonly used as an antineoplastic and immunosuppressive agent (1-3).

Cyclophosphamide is one of the universally known anti-neoplastic drugs whose therapeutic efficacy against hematological and solid malignancies and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis (4).

Cyclophosphamide is used in high doses for the chemotherapy of various forms of cancer, in low doses in the treatment of autoimmune diseases, and also as an immunosuppressant after organ transplants (5). Cyclophosphamide's chemically reactive metabolic products induce cytotoxicity by alkylating DNA and proteins (3). Cyclophosphamide is known as human carcinogen and has an increased incidence of chromosome aberrations in lymphocytes from patients with malignant and non-malignant diseases (6). The genotoxicity of cyclophosphamide has been studied in a variety of *in vivo* and *in vitro* systems, mutagenic, teratogenic and carcinogenic, and is routinely used as a positive control in genotoxicity tests (1, 6).

Natural compounds find application in the treatment of refractory diseases, a new trend in modern clinical medicine (7). *Nigella sativa* L. is a short-lived annual plant of the Ranunculaceae family, known as black seed, black cumin and fennel flower (8, 9). *N. sativa* is an aromatic plant with tremendous therapeutic properties such as hypotensive, gastroprotective, nephrocurative, nephroprotective, antioxidative, antimicrobial, genoprotective, neuroprotective, immunomodulatory, antiinflammatory, hypoglycemic, hypolipidemic, anticarcinogenic and hepatoprotective (9, 10). It increases the production of two substances, interferon and interleukin, the first defense shield of the immune system against tumor cells (11). *N. sativa* seeds are very rich in fixed oil, essential fatty acids, alkaloids, phytosterols, glycolipids and phospholipids, saponins and essential oil components. In seed essential oil; thymokinone, *p*-cymene and thymol are the active components.

Thymokinone has been shown as a cytotoxic agent in several human tumor cell lines resistant to various multidrug drugs (1). It has also been shown in another study that gastric cancer cells inhibit their growth (12). The effect of high dose thymokinone on stomach was found to be equal to Omeprazole (13). Molecular mechanisms underlying these anticancer effects; cell cycle arrest, apoptosis, oxidative damage of cellular macromolecules, blockade of tumor angiogenesis and inhibition of tumor migration (1). Micronucleus analysis methods are widely used in genotoxicity studies at chromosome level. The frequency of micronucleus

formation is considered to be an indicator of damage to the genetic material. Micronuclei are those that occur during cell division, originating from centric or acentric chromosome fragments that are not involved in the core nucleus (14).

In this study, it was aimed to show the healing effects of *N. sativa* oil at different concentrations against the genotoxic effects of cyclophosphamide by micronucleus test.

Materials and Methods

Materials

Micronucleus testing is usually performed in peripheral blood lymphocytes to determine genotoxicity in humans. Because in the studies performed, the increase in the micronucleus frequency in peripheral blood lymphocytes from cancer patients was found to be as much as the micronucleus frequency in the target tissue (15-17). *N. sativa* oil was obtained from a local vegetable urea shop and stored in dark brown bottles until use. It was dissolved in dimethyl sulfoxide and then applied to the cells at a final concentration of 1, 5 and 10 µg/mL. cyclophosphamide, cytochalasin B, RPMI medium, phytohemagglutinin, antibiotic, fetal calf serum, L-Glutamine and Giemsa solution were obtained from Sigma.

Methods

Micronucleus test was performed according to the method described by Fenech and Morley (18). For the analysis of micronucleus in binucleated lymphocytes, cell culture was established from 0.2 mL of fresh heparinized blood. Cells were treated with *N. sativa* oil at a final concentration of 1 µg/mL, 5 µg/mL, 10 µg/mL. Cytochalasin B was added to each tube at a final concentration of 6 µg/mL at 44 hours of incubation. After 24 hours of incubation at 37°C, the cells were centrifuged and micronucleus test in peripheral lymphocytes was performed. (18). Cells were harvested with hypotonic (0.4% KCl) and fixative (methanol: acetic acid) solution. Cell suspensions were stained with Giemsa after dropping onto clean glass slides. Cyclophosphamide was also used as a positive control. Cyclophosphamide was given to the tubes at a final concentration of 0.16 µg/mL. Micronucleus scoring was limited to binuclear lymphocytes with cytoplasm according to the criteria determined by Fenech et al. (19). 2000 binucleated lymphocytes were scored for each donor (8000 binucleated cells per concentration) (20).

Statistical Analysis

Windows for SPSS version 22 statistical software program was used to analyze the data. Experimental and control groups were analyzed with One way Anova. Arithmetic mean ($\bar{X}$) $\pm$ and standard deviation (SD) was determined. $P < 0.05$ was considered significant

Results

Micronucleus data in cells treated with cyclophosphamide and *N. sativa* oil and both are shown in table 1. Micronucleus frequency for the control group was determined as 3.5. Cyclophosphamide treatment increased the micronucleus ratio to 25.2. This value was significantly higher than the control group ($p < 0.05$). No significant increase in micronucleus frequency was observed when the application of *N. sativa* oil at concentrations of 1, 5, 10 µg/mL compared with the negative control. There was a decrease in the number of micronucleus in all three concentrations (1, 5, 10 µg/mL) compared to the cyclophosphamide group in the groups treated with *N. sativa* oil and cyclophosphamide (Table 1).

Table 1. Frequency of MN in cultured human lymphocytes treated with *N. sativa* oil.

Test substance	Concentrations	MN ($\bar{X} \pm SD$)
Control	-	3.5 $\pm$ 0.57
Cyclophosphamide	0.16 µg/mL	25.2 $\pm$ 3.8 ^a
<i>N. sativa</i> oil	1 µg/mL	3.5 $\pm$ 1.29 ^b
	5 µg/mL	5.25 $\pm$ 0.95 ^b
	10 µg/mL	2.75 $\pm$ 0.95 ^b

Cyclophosphamide + <i>N.sativa</i> oil	0.16 µg/mL+1	19.75±2.5 ^{ac}
	µg/mL	17.75±4.64
	0.16 µg/mL+5	20.5±3.55 ^{ac}
	µg/mL	
	0.16 µg/mL+10	
	µg/mL	

SD: Standard deviation, $p < 0.05$

2000 cells were scored for each tube.

^a: Significant difference from control

^b: Significant difference from cyclophosphamide

^c: Significant difference from *N.sativa* oil

Discussion

Phytotherapy is an area that uses plants as health promoting agents to treat diseases. In the conventional use of phytotherapies, the original composition of the plant or a certain percentage of certain components of the plant is generally used (21). Medicinal plants are considered to be the main source of potentially therapeutically effective new chemicals. According to the data of the World Health Organization, 70-80% of the population in developing countries relies on plants for primary health care (22). *N. sativa* oil, including the main components of thymoquinone and P-cymene, is considered to have anti-inflammatory, hepatoprotective and reno-protective effects (23). One of the most commonly used cytogenetic assays for genotoxic evaluation of different agents is CBMN (Cytokinesis Blocked Micronuclei) test in cultured human leukocytes (22). In this study we investigated the effect of *N. sativa* oil on genotoxicity in human leukocytes. *N. sativa* oil was used in different concentrations (1, 5, 10 µg/mL). Unlike our study, Abdel-Moneim et al. investigated the protective effects of *N. sativa* seeds against genotoxicity and chromosomal aberrations induced by carbon tetrachloride in mouse spermatocytes. In our study, the therapeutic effects of *N. sativa* oil were investigated in spite of the application of cyclophosphamide in lymphocyte cells from healthy individuals instead of mouse spermatocytes. Abdel-Moneim et al. Have shown that *N.sativa* is effective in the prevention of CCl₄-induced genetic damage in germ cells and can be used as an adjunct nutritional supplement in the early stages of exposure to mutagens. Similarly, in our study, it was observed that the amount of micronucleus decreased in the group in which cyclophosphamide was used together with *N. sativa* oil compared to the positive control group. (24). In the study of Galhena et al., a mixture of 100-600 µg/mL consisting of *N.sativa* seeds, *Hemidesmus indicus* roots and *Smilax glabra* rhizomes was applied to human lymphocyte culture together with bleomycin and chromosome aberrations such as dicentric chromosome, acentric fragment, chromatid fractures were examined. According to the results of this study; *N. sativa* seeds, *H. indicus* roots and *S. glabra* rhizomes showed that the mixture has the potential to protect against cytogenetic damage caused by bleomycin in human peripheral lymphocytes. In our study, *N. sativa* oil was used instead of *N. sativa* seeds and only micronucleus frequency was examined. However, when the results were examined, similar to the results of Galhena et al. (25). Hashem et al. concluded that *N. sativa* oil is potentially protective against carbendazim-induced hematoxicity, hepatotoxicity and genotoxicity. In this study, it was determined that *N.sativa* oil moderately improved in terms of micronucleus percentage and DNA fragmentation when applied together with carbendazim and mancozeb. In our study, positive control cyclophosphamide was used to determine the healing effect of *N. sativa* oil and in vitro cell culture experiments were performed (10). Al-Okbi et al. Investigated the effect of using *N. sativa* oil alone and in combination with fish oil in CCl₄ treated rats. According to the results of this study, it was observed that combined oral administration of *N. sativa* oil and fish oil / *N. sativa* oil combined with anti-inflammatory and antioxidant activity reduced liver

and kidney damage (23). Nguyen et al. in Morocco investigated the *in vitro* cytotoxicity, genotoxicity and antigenotoxicity of aqueous plant extracts from three different regions (Erfoud, Fkih ben Salah, Settati) by the neutral red uptake test in human C3A cells, the bacterial Vitotox, Ames assays, comet assay and micronucleus test. *N.sativa* seed extracts showed varying degrees of antigenotoxicity depending on where the test specimens came from. Extracts from Fkih ben Salah and Settati were reported to exhibit antigenotoxic effects by significantly reducing the micronucleus number at concentrations of 9 mg / mL. Similarly, in our study, the effects of *N. sativa* oil on micronucleus formation in healthy human lymphocyte cell culture at concentrations of 1, 5 and 10 µg / mL were examined and the genotoxic effects of cyclophosphamide used as positive control were reduced by *N. sativa* oil in all three concentrations. Although *N. sativa* oil concentrations and cell type used in our study were different from those of Nguyen et al., Similar results were found. However, the location of the samples, the test and other test conditions may affect the research result (26).

Conclusion

In this study, it was shown that *N. sativa* oil may have curative effects against mutation inducing agents. To understand the mechanism of the genotoxicity effects of *N. sativa* oil, molecular tests, testing of different concentrations and in vivo experiments are needed.

REFERENCES

1. Yuksel S, Tasdemir S, Korkmaz S. Protective effect of thymoquinone against cyclophosphamide-induced genotoxic damage in human lymphocytes. Bratisl Lek Listy. 2017;118(4):208-11. PubMed PMID: 28471230. Epub 2017/05/05.
2. Tuorkey MJ. Therapeutic Potential of *Nigella sativa* Oil Against Cyclophosphamide-Induced DNA Damage and Hepatotoxicity. Nutr Cancer. 2017 Apr;69(3):498-504. PubMed PMID: 28287318. Epub 2017/03/14.
3. Habibi E, Shokrzadeh M, Ahmadi A, Chabra A, Naghshvar F, Keshavarz-Maleki R. Genoprotective effects of Origanum vulgare ethanolic extract against cyclophosphamide-induced genotoxicity in mouse bone marrow cells. Pharm Biol. 2015 Jan;53(1):92-7. PubMed PMID: 25519883. Epub 2014/12/19.
4. Basu A, Bhattacharjee A, Samanta A, Bhattacharya S. Prevention of cyclophosphamide-induced hepatotoxicity and genotoxicity: Effect of an L-cysteine based oxovanadium(IV) complex on oxidative stress and DNA damage. Environ Toxicol Pharmacol. 2015 Nov;40(3):747-57. PubMed PMID: 26432771. Epub 2015/10/04.
5. Ince S, Kucukkurt I, Demirel HH, Acaroz DA, Akbel E, Cigerci IH. Protective effects of boron on cyclophosphamide induced lipid peroxidation and genotoxicity in rats. Chemosphere. 2014 Aug;108:197-204. PubMed PMID: 24530163. Epub 2014/02/18.
6. Doherty AT, Hayes J, Holme P, O'Donovan M. Chromosome aberration frequency in rat peripheral lymphocytes increases with repeated dosing with hexamethylphosphoramide or cyclophosphamide. Mutagenesis. 2012 Sep;27(5):533-9. PubMed PMID: 22492203. Epub 2012/04/12.
7. Ijaz H, Tulain UR, Qureshi J, Danish Z, Musayab S, Akhtar MF, et al. Review: *Nigella sativa* (Prophetic Medicine): A Review. Pak J Pharm Sci. 2017 Jan;30(1):229-34. PubMed PMID: 28603137. Epub 2017/06/13.
8. Edizer DT, Yigit O, Cinar Z, Gul M, Kara E, Yigitcan B, et al. Protective role of intratympanic *Nigella sativa* oil against gentamicin induced hearing loss. Int J Pediatr Otorhinolaryngol. 2017 Jun;97:83-8. PubMed PMID: 28483257. Epub 2017/05/10.
9. Mosbah R, Djerrou Z, Mantovani A. Protective effect of *Nigella sativa* oil against acetamiprid induced reproductive toxicity in male rats. Drug Chem Toxicol. 2018 Apr;41(2):206-12. PubMed PMID: 28669218. Epub 2017/07/04.
10. Hashem MA, Mohamed WAM, Attia ESM. Assessment of protective potential of *Nigella sativa* oil against carbendazim- and/or mancozeb-induced hematotoxicity,

hepatotoxicity, and genotoxicity. Environ Sci Pollut Res Int. 2018 Jan;25(2):1270-82. PubMed PMID: 29086361. Epub 2017/11/01.

11. Swamy SM, Tan BK. Cytotoxic and immunopotentiating effects of ethanolic extract of *Nigella sativa* L. seeds. J Ethnopharmacol. 2000 Apr;70(1):1-7. PubMed PMID: 10720783. Epub 2000/03/18.

12. Badary OA, Al-Shabanah OA, Nagi MN, Al-Rikabi AC, Elmazar MM. Inhibition of benzo(a)pyrene-induced forestomach carcinogenesis in mice by thymoquinone. Eur J Cancer Prev. 1999 Oct;8(5):435-40. PubMed PMID: 10548399. Epub 1999/11/05.

13. Magdy MA, Hanan el A, Nabila el M. Thymoquinone: Novel gastroprotective mechanisms. Eur J Pharmacol. 2012 Dec 15;697(1-3):126-31. PubMed PMID: 23051678. Epub 2012/10/12.

14. Norppa H, Falck GC. What do human micronuclei contain? Mutagenesis. 2003 May;18(3):221-33. PubMed PMID: 12714687. Epub 2003/04/26.

15. Kirsch-Volders M, Elhajouji A, Cundari E, Van Hummelen P. The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res. 1997 Aug 1;392(1-2):19-30. PubMed PMID: 9269328. Epub 1997/08/01.

16. Vanparys P, Vermeiren F, Sysmans M, Temmerman R. The micronucleus assay as a test for the detection of aneugenic activity. Mutat Res. 1990 Jun;244(2):95-103. PubMed PMID: 2113183. Epub 1990/06/01.

17. Cheng TJ, Christiani DC, Xu X, Wain JC, Wiencke JK, Kelsey KT. Increased micronucleus frequency in lymphocytes from smokers with lung cancer. Mutat Res. 1996 Jan 17;349(1):43-50. PubMed PMID: 8569791. Epub 1996/01/17.

18. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc. 2007;2(5):1084-104. PubMed PMID: 17546000. Epub 2007/06/05.

19. Fenech M, Chang WP, Kirsch-Volders M, Holland N, Bonassi S, Zeiger E, et al. HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat Res. 2003 Jan 10;534(1-2):65-75. PubMed PMID: 12504755. Epub 2002/12/31.

20. Ionescu ME, Ciocirlan M, Becheanu G, Nicolaie T, Ditescu C, Teiusanu AG, et al. Nuclear Division Index may Predict Neoplastic Colorectal Lesions. Maedica (Buchar). 2011 Jul;6(3):173-8. PubMed PMID: 22368693. Pubmed Central PMCID: PMC3282537. Epub 2012/03/01.

21. Falzon CC, Balabanova A. Phytotherapy: An Introduction to Herbal Medicine. Prim Care. 2017 Jun;44(2):217-27. PubMed PMID: 28501226. Epub 2017/05/16.

22. Milosevic-Djordjevic O, Radovic Jakovljevic M, Markovic A, Stankovic M, Ciric A, Marinkovic D, et al. Polyphenolic contents of *Teucrium polium* L. and *Teucrium scordium* L. associated with their protective effects against MMC-induced chromosomal damage in cultured human peripheral blood lymphocytes. Turk J Biol. 2018;42(2):152-62. PubMed PMID: 30814877. Pubmed Central PMCID: PMC6353277. Epub 2019/03/01.

23. Al-Okbi SY, Mohamed DA, Hamed TE, Edris AE, Fouda K. Hepatic Regeneration and Reno-Protection by Fish oil, *Nigella sativa* Oil and Combined Fish Oil/*Nigella sativa* Volatiles in CCl₄ Treated Rats. J Oleo Sci. 2018 Mar 1;67(3):345-53. PubMed PMID: 29459508. Epub 2018/02/21.

24. Abdel-Moneim AM, Essawy AE, Hamed SS, Abou-Gabal AA, Alzergy AA. Protective effect of *Nigella sativa* seeds against spermatocyte chromosomal aberrations and genotoxicity induced by carbon tetrachloride in mice. Environ Sci Pollut Res Int. 2017 Apr;24(12):11677-82. PubMed PMID: 28324259. Epub 2017/03/23.

25. Galhena BP, Samarakoon SSR, Thabrew MI, Paul SFD, Perumal V, Mani C. Protective Effect of a Polyherbal Aqueous Extract Comprised of *Nigella sativa* (Seeds),

Hemidesmus indicus (Roots), and Smilax glabra (Rhizome) on Bleomycin Induced Cytogenetic Damage in Human Lymphocytes. Biomed Res Int. 2017;2017:1856713. PubMed PMID: 28626752. Pubmed Central PMCID: PMC5463188. Epub 2017/06/20.

26. T. Nguyen HT, A. Hilali, R. Anthonissen, A. Maes, L. Verschaeve. In vitro toxicity, genotoxicity and antigenotoxicity of *Nigella sativa* extracts from different geographic locations. South African Journal of Botany. 2019;126:132-41.